GOP Committee Blocks Funding for Defense Department Psychedelics Trials

It’s a frustrating week for advocates of plant medicine. A GOP-led House committee just shot down a bipartisan plan to inject an extra $10 million into the Department of Defense for psychedelic clinical trials. This cash would have ramped up research into how substances like ibogaine and psilocybin can help active-duty service members. Even though the military is already required to run these trials, this extra funding was meant to widen the net and find real solutions for those dealing with trauma.

The silver lining? High-profile names from both sides of the aisle, along with veterans who’ve seen the benefits firsthand, are still pushing hard for access. From talk of government vouchers to new "centers for excellence" at VA facilities, the momentum isn't stopping. For regular tokers and the broader community, this matters because it shows the fight for therapeutic access is moving into the mainstream. When the military starts seriously studying these substances, it breaks down the stigma for everyone, paving the way for more legal, science-backed options in the future.